Vistagen Therapeutics, Inc. VTGN 深 滬
已收盤 05-08 16:00:00 美东时间
0.6105
+0.024
+4.04%
華盛通- 最 高0.64
- 今 開0.5974
- 成交量 118.17万股
- 最 低 0.5963
- 昨 收 0.5868
- 總市值 2418.82万
- 52周最高 5.14
- 市盈率 靜 --
- 換手率 2.98%
- 52周最低 0.43
- 委 比 12.09%
- 總股本 3962.03万
- 歷史最高 495.00
- 量 比 3.24
- 振 幅 7.45%
- 歷史最低 0.43
- 每 手 1
- 風險率 1.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
VistaGen Therapeutics ( ($VTGN) ) just unveiled an update. On May 8, 2026, Vist...
05-09 06:07
Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
05-08 19:42
VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
VistaGen Therapeutics ( ($VTGN) ) has shared an announcement. On April 22, 2026...
04-29 04:31
Vistagen Receives "Study May Proceed" Letter From FDA Under IND Application For Refisolone Nasal Spray For Treatment Of Vasomotor Symptoms Due To Menopause
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
04-22 20:35
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BNB Plus (NASDAQ:BNBX) stock moved upwards by 12.7% to $0.65 during Tu...
04-15 05:05
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation
The latest update is out from VistaGen Therapeutics ( ($VTGN) ). On March 16, 2...
03-17 04:29
Class action lawsuit targets VistaGen Therapeutics over alleged misleading clinical trial statements
Class action lawsuit targets VistaGen Therapeutics over alleged misleading clinical trial statements A securities class action lawsuit has been filed against VistaGen on behalf of shareholders who purchased securities between April 1, 2024 and December 16, 2025. The complaint alleges the company mad
03-11 21:03
BRIEF-Vistagen Therapeutics Implements 20% Workforce Reduction
BRIEF-Vistagen Therapeutics Implements 20% Workforce Reduction March 11 (Reuters) - VistaGen Therapeutics Inc VTGN.O : VISTAGEN THERAPEUTICS INC - IMPLEMENTS 20% WORKFORCE REDUCTION ON MARCH 5, 2026 - SEC FILING VISTAGEN THERAPEUTICS INC - REDUCTION SUPPORTS CASH MANAGEMENT AND PALISADE PROGRAM CLIN
03-11 19:14
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints
Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.
03-05 23:38
VistaGen Investors Face March 16 Deadline to Lead Securities Class Action
VistaGen Investors Face March 16 Deadline to Lead Securities Class Action Faruqi and Faruqi, LLP is investigating potential claims against VistaGen Therapeutics Inc. and has reminded investors of a March 16, 2026 deadline to seek lead-plaintiff status in a federal securities class action. The compla
03-03 21:41
